Agilent Thought Leader Award Presented to Renowned Drug Discovery Researcher Professor Jiandong Jiang Award to Chinese Scientist Supports the Use of Various Molecular Approaches to Cancer Research SANTA CLARA, Calif., November 12, 2017 Agilent Technologies Inc. (NYSE: A) today announced that Professor Jiandong Jiang has received an Agilent Thought Leader Award in support of his... Read more
Basel, 07 November 2017 FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease Approval based on data from a basket study, which enrolls participants across multiple diseases based predominantly on genetic profile Roche (SIX: RO, ROG; OTCQX: RHHBY) announced... Read more
Basel, 07 November 2017 FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer Approval based on phase III results that showed Alecensa extended the average time that people lived without their disease worsening compared to crizotinib Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food... Read more
Basel, 01 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia A with inhibitors will be featured New data for polatuzumab vedotin in a difficult-to-treat blood cancer, which led to... Read more
Basel, 01 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia A with inhibitors will be featured New data for polatuzumab vedotin in a difficult-to-treat blood cancer, which led to... Read more
AUSTIN, Texas, Oct. 31, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Group A Strep Assay, a moderate complexity, sample to answer test for the direct detection of Streptococcus pyogenes from throat swab specimens using the ARIES® System. This is the sixth assay the FDA has... Read more
AUSTIN, Texas, Oct. 31, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Group A Strep Assay, a moderate complexity, sample to answer test for the direct detection of Streptococcus pyogenes from throat swab specimens using the ARIES® System. This is the sixth assay the FDA has... Read more
26 October 2017 FDA accepts Roche’s supplemental Biologics License Application for Avastin as a front-line treatment for women with advanced ovarian cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Avastin® (bevacizumab) in combination with chemotherapy (carboplatin... Read more
Shimadzu Corporation and the IAEA (International Atomic Energy Agency, headquartered in Vienna, Austria)*1 have agreed on the donation of a Shimadzu LCMS-8060 High-Performance Liquid Chromatograph Mass Spectrometer*2 to the agency. IAEA Director General Yukiya Amano and Shimadzu Corporation Chairman Akira Nakamoto attended the signing ceremony for the Memorandum of Cooperation at Shimadzu Corporation Head Office... Read more
Shimadzu Corporation and the IAEA (International Atomic Energy Agency, headquartered in Vienna, Austria)*1 have agreed on the donation of a Shimadzu LCMS-8060 High-Performance Liquid Chromatograph Mass Spectrometer*2 to the agency. IAEA Director General Yukiya Amano and Shimadzu Corporation Chairman Akira Nakamoto attended the signing ceremony for the Memorandum of Cooperation at Shimadzu Corporation Head Office... Read more